These two studies, Dr. Poddubnyy continued, point the way toward maximizing the risk/benefit ratio of NSAID therapy in patients with AS.
The German registry study was funded by the German Rheumatism Research Center of Berlin. Dr. Poddubnyy reported having no financial conflicts.